ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Tu2038 All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study
Gastroenterology
◽
10.1016/s0016-5085(14)63284-4
◽
2014
◽
Vol 146
(5)
◽
pp. S-903
◽
Cited By ~ 1
Author(s):
Ira M. Jacobson
◽
Patrick Marcellin
◽
Alessandra Mangia
◽
Paul Y. Kwo
◽
Graham Foster
◽
...
Keyword(s):
Fixed Dose Combination
◽
Fixed Dose
◽
Genotype 1
◽
Phase 3
◽
Treatment Naïve
◽
Dose Combination
Download Full-text
Related Documents
Cited By
References
Faculty Opinions recommendation of Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.725431366.793505980
◽
2015
◽
Author(s):
Philip Rosenthal
Keyword(s):
Hepatitis C
◽
Japanese Patients
◽
Fixed Dose Combination
◽
Fixed Dose
◽
Genotype 1
◽
Open Label
◽
Phase 3
◽
Treatment Naïve
◽
Dose Combination
◽
Previously Treated
Download Full-text
O164 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-1 STUDY
Journal of Hepatology
◽
10.1016/s0168-8278(14)61459-8
◽
2014
◽
Vol 60
(1)
◽
pp. S523-S524
◽
Cited By ~ 3
Author(s):
A. Mangia
◽
P. Marcellin
◽
P. Kwo
◽
G.R. Foster
◽
M. Buti
◽
...
Keyword(s):
Fixed Dose Combination
◽
Fixed Dose
◽
Genotype 1
◽
Phase 3
◽
Treatment Naïve
◽
Dose Combination
Download Full-text
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial
The Lancet Infectious Diseases
◽
10.1016/s1473-3099(15)70099-x
◽
2015
◽
Vol 15
(6)
◽
pp. 645-653
◽
Cited By ~ 255
Author(s):
Masashi Mizokami
◽
Osamu Yokosuka
◽
Tetsuo Takehara
◽
Naoya Sakamoto
◽
Masaaki Korenaga
◽
...
Keyword(s):
Hepatitis C
◽
Japanese Patients
◽
Fixed Dose Combination
◽
Fixed Dose
◽
Genotype 1
◽
Open Label
◽
Phase 3
◽
Treatment Naïve
◽
Dose Combination
◽
Previously Treated
Download Full-text
All oral fixed-dose combination Sofosbuvir/Ledipasvir with or without Ribavirin for 12 or 24 weeks in treatment-naive genotype 1 HCV-infected patients: the phase 3 ION-1 study
Zeitschrift für Gastroenterologie
◽
10.1055/s-0034-1385996
◽
2014
◽
Vol 52
(08)
◽
Author(s):
P Buggisch
◽
T Göser
◽
AW Lohse
◽
T Berg
◽
P Galle
◽
...
Keyword(s):
Fixed Dose Combination
◽
Fixed Dose
◽
Genotype 1
◽
Phase 3
◽
Treatment Naïve
◽
Dose Combination
Download Full-text
Phase 3 randomized, controlled clinical trial of bictegravir coformulated with FTC/TAF in a fixed-dose combination (B/F/TAF) vs dolutegravir (DTG) + F/TAF in treatment-naïve HIV-1 positive adults: week 48 results
10.26226/morressier.5aeaf2d35800a00019097f85
◽
2018
◽
Author(s):
Christian Wisskirchen
◽
Hans-Jürgen Stellbrink
Keyword(s):
Clinical Trial
◽
Fixed Dose Combination
◽
Fixed Dose
◽
Controlled Clinical Trial
◽
Randomized Controlled Clinical Trial
◽
Phase 3
◽
Randomized Controlled
◽
Treatment Naïve
◽
Dose Combination
◽
Hiv 1
Download Full-text
O109 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-2 STUDY
Journal of Hepatology
◽
10.1016/s0168-8278(14)60111-2
◽
2014
◽
Vol 60
(1)
◽
pp. S45
◽
Cited By ~ 1
Author(s):
N. Afdhal
◽
R.K. Reddy
◽
P. Pockros
◽
A.M. Di Bisceglie
◽
S. Arora
◽
...
Keyword(s):
Fixed Dose Combination
◽
Fixed Dose
◽
Genotype 1
◽
Phase 3
◽
Dose Combination
Download Full-text
A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus
Hepatology International
◽
10.1007/s12072-016-9726-5
◽
2016
◽
Vol 10
(6)
◽
pp. 947-955
◽
Cited By ~ 14
Author(s):
Young-Suk Lim
◽
Sang Hoon Ahn
◽
Kwan Sik Lee
◽
Seung Woon Paik
◽
Youn-Jae Lee
◽
...
Keyword(s):
Hepatitis C Virus
◽
Hepatitis C
◽
Fixed Dose Combination
◽
Fixed Dose
◽
Genotype 1
◽
Combination Tablet
◽
Korean Patients
◽
Phase Iiib
◽
Treatment Naïve
◽
Dose Combination
Download Full-text
A phase 3 randomized controlled clinical trial of bictegravir in a fixed dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-naïve adults at week 48
10.26226/morressier.5aeaf2d35800a00019097f7f
◽
2018
◽
Author(s):
Jürgen K. Rockstroh
◽
Christian Wisskirchen
Keyword(s):
Clinical Trial
◽
Fixed Dose Combination
◽
Fixed Dose
◽
Controlled Clinical Trial
◽
Randomized Controlled Clinical Trial
◽
Phase 3
◽
Randomized Controlled
◽
Treatment Naïve
◽
Dose Combination
Download Full-text
236 All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Experienced Genotype 1 HCVInfected Patients: The Phase 3 Ion-2 Study
Gastroenterology
◽
10.1016/s0016-5085(14)63287-x
◽
2014
◽
Vol 146
(5)
◽
pp. S-904
Author(s):
Paul Y. Kwo
◽
K. Rajender Reddy
◽
Paul J. Pockros
◽
Adrian M. Di Bisceglie
◽
Sanjeev Arora
◽
...
Keyword(s):
Fixed Dose Combination
◽
Fixed Dose
◽
Genotype 1
◽
Phase 3
◽
Dose Combination
Download Full-text
Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe fibrosis
Liver International
◽
10.1111/liv.14502
◽
2020
◽
Vol 40
(8)
◽
pp. 1853-1859
◽
Cited By ~ 4
Author(s):
Armand Abergel
◽
Tarik Asselah
◽
Arianne Mallat
◽
Brigitte Chanteranne
◽
Frederic Faure
◽
...
Keyword(s):
Fixed Dose Combination
◽
Fixed Dose
◽
Open Label
◽
Phase 3
◽
Open Label Study
◽
Label Study
◽
Treatment Naïve
◽
Dose Combination
◽
Severe Fibrosis
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close